Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: The ValTop study

Gianfranco Parati, Roland Asmar, Grzegorz Bilo, Albert Kandra, Robert Di Giovanni, Thomas Mengden

Research output: Contribution to journalArticlepeer-review


Early combination therapy is increasingly recommended in hypertension management because of increased risk of adverse effects with high-dose monotherapy. However, this risk is not necessarily increased for high doses of angiotensin receptor blockers (ARB). ValTop study compared efficacy and safety of high vs. conventional dose of valsartan in hypertensive patients. ValTop was a controlled, randomized, double-blind trial. Of 6035 screened subjects, 4004 mild-to-moderate hypertensive patients (mean seated diastolic blood pressure (MSDBP) 90-109 mm Hg) started 4-week open-label treatment with valsartan 160 mg. Of them, 3776 were randomized to receive valsartan 160 mg (N=1900) or 320 mg (N=1876) o.d. for 4 weeks. In 28-week open-label extension study, all participating patients (N=642) received valsartan 320 mg. Valsartan 160 mg reduced MSDBP by 10.0 mm Hg in the initial open-label phase. Further BP reductions in the double-blind phase were significantly (P

Original languageEnglish
Pages (from-to)986-994
Number of pages9
JournalHypertension Research
Issue number10
Publication statusPublished - Oct 2010


  • angiotensin receptor blockers
  • antihypertensive therapy
  • arterial hypertension
  • clinical trials
  • monotherapy

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: The ValTop study'. Together they form a unique fingerprint.

Cite this